Search Results

in-vitro measurement of IqA anticardiolipin antibodies in human serum, as an aid in the diagnosis of antiphospholipid syndrome (APS).

Not Found

Here's an analysis of the provided text regarding the acceptance criteria and study for the "Anticardiolipin IgA Screen EIA Kit" (Trade Name) / "BINDAZYME® Anticardiolipin IgA EIA Kit" (Device Name):

It's important to note that the provided text is an FDA 510(k) clearance letter. This type of document primarily confirms substantial equivalence to a predicate device and permits marketing, rather than detailing full study results or specific acceptance criteria met. Therefore, much of the requested information (like specific test set sizes, expert qualifications, and detailed statistical results) is not present in this document. The FDA letter references a 510(k) submission, which would contain such details, but the letter itself does not.

However, based on the provided text, we can infer some information and identify what is explicitly missing.

1. Table of Acceptance Criteria and Reported Device Performance

This information is not provided in the FDA clearance letter. The letter states that the device is "substantially equivalent" to legally marketed predicate devices, implying that its performance is comparable. It does not list specific sensitivity, specificity, or agreement percentages as acceptance criteria or reported performance for this device.

2. Sample size used for the test set and the data provenance

This information is not provided in the FDA clearance letter. The letter refers to a 510(k) submission, which would contain details about the study.

3. Number of experts used to establish the ground truth for the test set and the qualifications of those experts

This information is not provided in the FDA clearance letter.

4. Adjudication method for the test set

This information is not provided in the FDA clearance letter.

5. If a multi-reader multi-case (MRMC) comparative effectiveness study was done, If so, what was the effect size of how much human readers improve with AI vs without AI assistance

An MRMC study is relevant for AI-assisted diagnostic devices. This device is an "Anticardiolipin IgA Screen EIA Kit," which is an in-vitro diagnostic (IVD) immunoassay kit, not an AI-powered image analysis or diagnostic assist device. Therefore, an MRMC study is not applicable to this type of device and would not have been conducted.

6. If a standalone (i.e. algorithm only without human-in-the-loop performance) was done

This device is an IVD kit, not an algorithm. Its performance is inherent to the kit itself, which is used by laboratory personnel. The concept of "standalone algorithm performance" is not applicable to this type of device.

7. The type of ground truth used (expert consensus, pathology, outcomes data, etc.)

The indications for use state "as an aid in the diagnosis of antiphospholipid syndrome (APS)." For an IVD measuring antibodies, the ground truth would typically be established through:

• Correlation with clinical diagnosis of APS (possibly based on expert clinical criteria, further laboratory tests, and patient outcomes).
• Comparison to a reference method or a well-characterized set of patient samples (e.g., samples from patients with confirmed APS and healthy controls).
• The FDA letter does not specify the exact ground truth methodology used in the underlying study.

8. The sample size for the training set

This information is not provided in the FDA clearance letter. For an IVD kit, the concept of a "training set" doesn't directly apply in the same way it does for machine learning algorithms. However, there would have been a development and validation phase where the kit's reagents and assay parameters were optimized using various sample cohorts. The size of these cohorts is not mentioned.

9. How the ground truth for the training set was established

As with the test set, the specifics are not provided. However, for an IVD, the ground truth for any development or validation cohort would similarly involve well-characterized patient samples with and without APS, or comparison against established reference methods for anticardiolipin IgA.

Summary of what is known from the provided text:

• Device Name: BINDAZYME® Anticardiolipin IgA EIA Kit
• Intended Use: In-vitro measurement of IgA anticardiolipin antibodies in human serum, as an aid in the diagnosis of antiphospholipid syndrome (APS).
• Regulatory Context: FDA 510(k) clearance, found substantially equivalent to a predicate device.
• Device Type: In-vitro diagnostic (IVD) immunoassay kit.

What is NOT known from the provided text (and would typically be in the full 510(k) submission):

• Specific performance metrics (sensitivity, specificity, accuracy).
• Detailed acceptance criteria for these metrics.
• Sample sizes for validation studies.
• Details about the patient cohorts (provenance, demographics).
• Exact ground truth establishment methods (beyond general implication for an IVD).
• Any information related to expert review or adjudication.

Ask a specific question about this device